Pictilisib also known as GDC-0941 is a highly selective orally active class I PI3K inhibitor that has shown promising efficacy with tolerable side effects in preclinical advanced breast cancer and solid tumors, however in human trials clinical regression of tumors was not seen. This evidence concerns the gene PIK3CA and breast cancer.